Oramed Joins Russell 2000 and 3000 Indexes, Strengthening Financial Position
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- Strengthened Financial Position: As of March 31, 2026, Oramed's total cash and assets amount to approximately $270 million, following a $10.5 million dividend payment, indicating a robust financial foundation that supports future investments and growth.
- Significant Loan Repayment: Oramed has repaid approximately $118 million of its loan to Scilex, with an expected recovery of around $43 million by October 2026, achieving a total recovery rate of 161%, which provides substantial capital returns for the company.
- Alpha Tau Investment Returns: Oramed's investment in Alpha Tau stands at approximately $38.2 million, with a current value of about $167 million, highlighting the company's potential in cancer treatment, particularly through its exclusive commercialization partnership in the prostate cancer market.
- Increased Market Recognition: Oramed is set to join the Russell 2000 and 3000 indexes, which is expected to enhance its visibility among investors, broaden its shareholder base, and improve stock liquidity, further supporting the company's long-term strategic development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORMP
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oramed Joins Russell 2000 and 3000 Indexes, Strengthening Financial Position
- Strengthened Financial Position: As of March 31, 2026, Oramed's total cash and assets amount to approximately $270 million, following a $10.5 million dividend payment, indicating a robust financial foundation that supports future investments and growth.
- Significant Loan Repayment: Oramed has repaid approximately $118 million of its loan to Scilex, with an expected recovery of around $43 million by October 2026, achieving a total recovery rate of 161%, which provides substantial capital returns for the company.
- Alpha Tau Investment Returns: Oramed's investment in Alpha Tau stands at approximately $38.2 million, with a current value of about $167 million, highlighting the company's potential in cancer treatment, particularly through its exclusive commercialization partnership in the prostate cancer market.
- Increased Market Recognition: Oramed is set to join the Russell 2000 and 3000 indexes, which is expected to enhance its visibility among investors, broaden its shareholder base, and improve stock liquidity, further supporting the company's long-term strategic development.
See More
Bio-Techne Soars Over 20% on Merck Acquisition News
- Acquisition News Boosts Stock: Bio-Techne Corp. (TECH) shares surged over 20% following the announcement of its acquisition by Merck KGaA for $73 per share, representing a total enterprise value of approximately $11.3 billion, which is a 36% premium to its one-month volume weighted average price, indicating strong market confidence in the deal.
- Strong Financial Performance: Bio-Techne generated over $1.2 billion in net sales for fiscal year 2025, and the acquisition is expected to immediately enhance Merck KGaA's profitability, improving both its Life Science business and overall EBITDA pre-margin, showcasing the strategic value of the acquisition.
- Cost Savings Expectations: Merck KGaA anticipates achieving approximately €140 million in annual cost savings by the third year post-transaction, indicating significant operational efficiency gains that will further bolster the company's financial health.
- Transaction Timeline: The deal is expected to close by late 2026 or early 2027, marking a significant integration for Bio-Techne in the biotech sector, which may influence future market competitive dynamics.
See More
Oramed Pharmaceuticals Joins Russell Indexes, Strengthens Financial Position
- Russell Index Inclusion: Oramed Pharmaceuticals is set to be added to the Russell 2000 and Russell 3000 indexes on June 29, 2026, which is expected to enhance the company's visibility, broaden its shareholder base, and improve trading liquidity.
- Significant Loan Recovery: Oramed's investment in Scilex was approximately $99.5 million, and to date, it has recouped about $118 million, with an expected additional recovery of $43 million by October 2026, resulting in an overall return of 161%, showcasing strong capital recovery capabilities.
- Strong Financial Position: As of March 31, 2026, Oramed reported total cash and assets of approximately $270 million, providing a solid foundation for future investments and growth opportunities.
- Diversified Strategic Investments: Oramed has made significant investments in companies like Alpha Tau and Lifeward, with Alpha Tau's current valuation at approximately $167 million, highlighting its potential in the biomedical sector and further strengthening the company's investment portfolio.
See More
Oramed Pharmaceuticals Reports $10 Million Profit in Q4
- Quarterly Profit Performance: Oramed Pharmaceuticals reported a profit of $10 million in Q4, translating to a net income of $0.24 per share, indicating the company's stability and profitability in the market, although adjusted losses were $0.06 per share due to non-recurring gains.
- Annual Performance Review: For the year, the company achieved a profit of $64.1 million, or $1.50 per share, reflecting sustained growth despite only $2 million in revenue, highlighting a gap between profitability and revenue growth.
- Market Reaction Expectations: Despite low revenue, Oramed's profitability may attract investor interest, especially in the biopharmaceutical sector where improved profitability is often seen as a positive signal for future growth potential.
- Financial Health Status: The company demonstrates strong profitability despite revenue challenges, showcasing potential in cost control and operational efficiency, which may lay the groundwork for future investments and expansion.
See More
LIFEWARD FINALIZES STRATEGIC PARTNERSHIP WITH ORAMED
- Partnership Announcement: LifeWard has successfully closed a strategic partnership with Oramed Pharmaceuticals.
- Focus on Innovation: The collaboration aims to enhance the development of innovative therapies, particularly in the field of diabetes treatment.
See More
LIFEWARD SECURES SHAREHOLDER CONSENT TO FINALIZE STRATEGIC ALLIANCE WITH ORAMED, FORMING A DIVERSIFIED BIOMEDICAL FIRM
Shareholder Approval: LifeWard has received approval from its shareholders to proceed with a strategic partnership.
Partnership with Oramed: The partnership involves collaboration with Oramed, focusing on the development of diversified biomedical solutions.
See More
Oramed Joins Russell 2000 and 3000 Indexes, Strengthening Financial Position
- Strengthened Financial Position: As of March 31, 2026, Oramed's total cash and assets amount to approximately $270 million, following a $10.5 million dividend payment, indicating a robust financial foundation that supports future investments and growth.
- Significant Loan Repayment: Oramed has repaid approximately $118 million of its loan to Scilex, with an expected recovery of around $43 million by October 2026, achieving a total recovery rate of 161%, which provides substantial capital returns for the company.
- Alpha Tau Investment Returns: Oramed's investment in Alpha Tau stands at approximately $38.2 million, with a current value of about $167 million, highlighting the company's potential in cancer treatment, particularly through its exclusive commercialization partnership in the prostate cancer market.
- Increased Market Recognition: Oramed is set to join the Russell 2000 and 3000 indexes, which is expected to enhance its visibility among investors, broaden its shareholder base, and improve stock liquidity, further supporting the company's long-term strategic development.
See More
Bio-Techne Soars Over 20% on Merck Acquisition News
- Acquisition News Boosts Stock: Bio-Techne Corp. (TECH) shares surged over 20% following the announcement of its acquisition by Merck KGaA for $73 per share, representing a total enterprise value of approximately $11.3 billion, which is a 36% premium to its one-month volume weighted average price, indicating strong market confidence in the deal.
- Strong Financial Performance: Bio-Techne generated over $1.2 billion in net sales for fiscal year 2025, and the acquisition is expected to immediately enhance Merck KGaA's profitability, improving both its Life Science business and overall EBITDA pre-margin, showcasing the strategic value of the acquisition.
- Cost Savings Expectations: Merck KGaA anticipates achieving approximately €140 million in annual cost savings by the third year post-transaction, indicating significant operational efficiency gains that will further bolster the company's financial health.
- Transaction Timeline: The deal is expected to close by late 2026 or early 2027, marking a significant integration for Bio-Techne in the biotech sector, which may influence future market competitive dynamics.
See More
Oramed Pharmaceuticals Joins Russell Indexes, Strengthens Financial Position
- Russell Index Inclusion: Oramed Pharmaceuticals is set to be added to the Russell 2000 and Russell 3000 indexes on June 29, 2026, which is expected to enhance the company's visibility, broaden its shareholder base, and improve trading liquidity.
- Significant Loan Recovery: Oramed's investment in Scilex was approximately $99.5 million, and to date, it has recouped about $118 million, with an expected additional recovery of $43 million by October 2026, resulting in an overall return of 161%, showcasing strong capital recovery capabilities.
- Strong Financial Position: As of March 31, 2026, Oramed reported total cash and assets of approximately $270 million, providing a solid foundation for future investments and growth opportunities.
- Diversified Strategic Investments: Oramed has made significant investments in companies like Alpha Tau and Lifeward, with Alpha Tau's current valuation at approximately $167 million, highlighting its potential in the biomedical sector and further strengthening the company's investment portfolio.
See More
Oramed Pharmaceuticals Reports $10 Million Profit in Q4
- Quarterly Profit Performance: Oramed Pharmaceuticals reported a profit of $10 million in Q4, translating to a net income of $0.24 per share, indicating the company's stability and profitability in the market, although adjusted losses were $0.06 per share due to non-recurring gains.
- Annual Performance Review: For the year, the company achieved a profit of $64.1 million, or $1.50 per share, reflecting sustained growth despite only $2 million in revenue, highlighting a gap between profitability and revenue growth.
- Market Reaction Expectations: Despite low revenue, Oramed's profitability may attract investor interest, especially in the biopharmaceutical sector where improved profitability is often seen as a positive signal for future growth potential.
- Financial Health Status: The company demonstrates strong profitability despite revenue challenges, showcasing potential in cost control and operational efficiency, which may lay the groundwork for future investments and expansion.
See More
LIFEWARD FINALIZES STRATEGIC PARTNERSHIP WITH ORAMED
- Partnership Announcement: LifeWard has successfully closed a strategic partnership with Oramed Pharmaceuticals.
- Focus on Innovation: The collaboration aims to enhance the development of innovative therapies, particularly in the field of diabetes treatment.
See More
LIFEWARD SECURES SHAREHOLDER CONSENT TO FINALIZE STRATEGIC ALLIANCE WITH ORAMED, FORMING A DIVERSIFIED BIOMEDICAL FIRM
Shareholder Approval: LifeWard has received approval from its shareholders to proceed with a strategic partnership.
Partnership with Oramed: The partnership involves collaboration with Oramed, focusing on the development of diversified biomedical solutions.
See More
